How do uterine sarcomas form?

The formation of uterine sarcoma may be related to genetic factors, abnormal hormone levels, radiation exposure, genetic mutations, and previous pelvic radiotherapy history. Uterine sarcoma is a malignant tumor originating from uterine smooth muscle or endometrial stroma. It usually presents with symptoms such as abnormal vaginal bleeding, pelvic pain, and abdominal mass.

1. Genetic factors

Some patients with uterine sarcoma have familial genetic tendencies, which may be related to mutations in tumor suppressor genes such as TP53 and RB1. Such patients are often accompanied by genetic diseases such as Lynch syndrome. It is recommended that those with a family history undergo regular gynecological examinations. If necessary, they can use medroxyprogesterone acetate tablets, leuprolide acetate microspheres for injection and other drugs to adjust hormone levels as directed by the doctor, or consider preventive surgical intervention.

2. Abnormal hormone levels

Long-term estrogen overstimulation may induce uterine sarcoma, which is common in postmenopausal women using unopposed estrogen replacement therapy. Patients may be accompanied by symptoms such as endometrial thickening and menstrual disorders. Tamoxifen Citrate Tablets, Letrozole Tablets and other drugs are commonly used clinically to regulate hormones. In severe cases, total hysterectomy is required.

3. Radiation exposure

People who have received radiation therapy to the pelvic area are at a significantly increased risk of developing uterine sarcomas. Radiation may cause DNA damage and malignant transformation of cells. These patients often develop symptoms years after radiation therapy and require early screening with imaging studies such as pelvic MRI. Treatment needs to be combined with tumor staging, wide hysterectomy or combined with radiotherapy and chemotherapy.

4. Gene mutation

Somatic mutations in genes such as MED12 can lead to the occurrence of uterine leiomyosarcoma, and the mutated cells acquire the ability to proliferate indefinitely. Patients' tumor tissues often show obvious nuclear atypia and increased pathological mitoses. Targeted therapies such as pazopanib capsules and trabectedin injection may be effective in some gene mutation sarcomas.

5. Previous history of pelvic radiotherapy

Radiation-related sarcoma may develop secondary to radiotherapy for pelvic malignant tumors such as cervical cancer, and the incubation period can reach more than 10 years. This type of sarcoma is highly malignant and prone to lung metastasis. Treatment requires expanded surgical scope combined with chemotherapy drugs such as ifosfamide injection and doxorubicin liposome injection.

To prevent uterine sarcoma, regular gynecological examinations are required, especially those with high-risk factors should undergo annual ultrasound examinations. Maintain a healthy lifestyle and avoid long-term use of estrogen drugs. Seek medical attention promptly when abnormal vaginal bleeding or pelvic mass occurs. Early diagnosis can lead to a better prognosis through radical surgery. After surgery, patients need to follow the doctor's instructions for regular review and monitor tumor markers and imaging changes.